<SEC-DOCUMENT>0001193125-18-050327.txt : 20180220
<SEC-HEADER>0001193125-18-050327.hdr.sgml : 20180220
<ACCEPTANCE-DATETIME>20180220160202
ACCESSION NUMBER:		0001193125-18-050327
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20180215
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20180220
DATE AS OF CHANGE:		20180220

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
		CENTRAL INDEX KEY:			0001299130
		STANDARD INDUSTRIAL CLASSIFICATION:	LABORATORY ANALYTICAL INSTRUMENTS [3826]
		IRS NUMBER:				161590339
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-34899
		FILM NUMBER:		18624517

	BUSINESS ADDRESS:	
		STREET 1:		1305 O'BRIEN DRIVE
		CITY:			MENLO PARK
		STATE:			CA
		ZIP:			94025
		BUSINESS PHONE:		650-521-8000

	MAIL ADDRESS:	
		STREET 1:		1305 O'BRIEN DRIVE
		CITY:			MENLO PARK
		STATE:			CA
		ZIP:			94025

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PACIFIC BIOSCIENCES OF CALIFORNIA INC
		DATE OF NAME CHANGE:	20050829

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NANOFLUIDICS INC
		DATE OF NAME CHANGE:	20040729
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d522689d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, DC 20549 </B></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">8-K</FONT> </B></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT
REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to Section&nbsp;13 or 15(d) of </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>The Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>February&nbsp;15, 2018 </B></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Pacific
Biosciences of California, Inc. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">001-34899</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">16-1590339</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(IRS Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>1305 O&#146;Brien Drive </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Menlo Park, California 94025 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive offices, including zip code) </B></P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(650) <FONT STYLE="white-space:nowrap">521-8000</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Registrant&#146;s telephone number, including area code) </B></P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former name or former address, if changed since last report) </B></P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <FONT STYLE="white-space:nowrap">8-K</FONT> filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions (see General Instruction A.2): </P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to Rule <FONT STYLE="white-space:nowrap">14a-12</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.14a-12)</FONT> </TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to Rule <FONT STYLE="white-space:nowrap">14d-2(b)</FONT> under the Exchange Act (17 CFR
<FONT STYLE="white-space:nowrap">240.14d-2(b))</FONT> </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to Rule <FONT STYLE="white-space:nowrap">13e-4(c)</FONT> under the Exchange Act (17 CFR
<FONT STYLE="white-space:nowrap">240.13e-4(c))</FONT> </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Securities Exchange Act of 1934 <FONT STYLE="white-space:nowrap">(&#167;240.12b-2</FONT> of this chapter).
</P> <P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Emerging growth company&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section&nbsp;13(a) of the Exchange Act.&nbsp;&nbsp;&#9744; </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;8.01.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Other Events. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to that certain underwriting agreement dated February&nbsp;13, 2018 (the
&#147;<U>Underwriting Agreement</U>&#148;), by and between Pacific Biosciences of California,&nbsp;Inc. (the &#147;<U>Company</U>&#148;) and Cantor Fitzgerald&nbsp;&amp; Co., as representative of the several underwriters named in Schedule A thereto
(the &#147;<U>Underwriters</U>&#148;) relating to the public offering (the &#147;<U>Offering</U>&#148;) of 12,500,000 shares of the Company&#146;s common stock, $0.001 par value per share (the &#147;Common Stock&#148;), at a price to the public of
$2.40 per share, the Company granted the Underwriters a <FONT STYLE="white-space:nowrap">30-day</FONT> option to purchase up to an additional 1,875,000 shares of Common Stock (the &#147;<U>Option Shares</U>&#148;). The Underwriters notified the
Company of the exercise in full of their option to purchase the additional shares on February&nbsp;15, 2018, and the sale of shares of Common Stock subject to such option, closed on February&nbsp;20, 2018.&nbsp;The net proceeds to the Company from
the sale of the Option Shares, after deducting the underwriting discount and estimated offering expenses payable by the Company, are expected to be approximately $4.3&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The shares of Common Stock are being offered and sold pursuant to the Company&#146;s shelf registration statement on
<FONT STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-219642)</FONT> (the &#147;Registration Statement&#148;), which was declared effective by the Securities and Exchange Commission (the
&#147;<U>SEC</U>&#148;) on August&nbsp;18, 2017, as supplemented by a preliminary prospectus supplement, dated February&nbsp;12, 2018, and a final prospectus supplement, dated February&nbsp;13, 2018, filed with the SEC pursuant to
Rule&nbsp;424(b)&nbsp;under the Securities Act of 1933, as amended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the sale of the Option Shares, the legal opinion as to the
legality of the Common Stock sold is being filed as Exhibit&nbsp;5.1 to this Current Report on <FONT STYLE="white-space:nowrap">Form&nbsp;8-K</FONT> and is incorporated herein and into the Registration Statement by reference. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;9.01.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Financial Statements and Exhibits. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d)&nbsp;Exhibits. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:25.30pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:39.50pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>5.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d522689dex51.htm">Opinion of Wilson Sonsini Goodrich&nbsp;&amp; Rosati, P.C. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d522689dex51.htm">Consent of Wilson Sonsini Goodrich&nbsp;&amp; Rosati, P.C. (included in Exhibit&nbsp;5.1 hereto).</A></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Pacific Biosciences of California, Inc.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ Susan K. Barnes</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Susan K. Barnes</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Executive&nbsp;Vice&nbsp;President,&nbsp;Chief&nbsp;Financial&nbsp;Officer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>and Principal Accounting Officer</B></P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: February&nbsp;20, 2018 </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>d522689dex51.htm
<DESCRIPTION>EX-5.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-5.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 5.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle">


<IMG SRC="g522689g37f45.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">650 Page Mill Road</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Palo Alto, CA 94304-1050</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt" align="left">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">PHONE 650.493.9300</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">FAX
650.493.6811</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt" align="left">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>www.wsgr.com</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">February&nbsp;20, 2018 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pacific Biosciences of California, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1305 O&#146;Brien Drive
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Menlo Park, CA 94025 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have acted as counsel to Pacific Biosciences of California, Inc., a Delaware corporation (the &#147;Company&#148;), in connection with the
filing by the Company with the Securities and Exchange Commission (the &#147;Commission&#148;) of a Registration Statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> (Registration No.&nbsp;333-219642), as amended (the &#147;Registration
Statement&#148;), under the Securities Act of 1933, as amended (the &#147;Act&#148;), and declared effective on August&nbsp;18, 2017. Pursuant to the Registration Statement, the Company has issued and sold 1,875,000 shares of its common stock $0.001
par value per share (the &#147;Shares&#148;) pursuant to that certain underwriting agreement, dated February&nbsp;13, 2018 (the &#147;Underwriting Agreement&#148;), by and between the Company and Cantor Fitzgerald&nbsp;&amp; Co., as representative
of the several underwriters named in Schedule A thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have examined the Registration Statement, together with the documents
incorporated by reference therein; the related prospectus, dated August&nbsp;18, 2017, filed with the Registration Statement (the &#147;Base Prospectus&#148;); the preliminary prospectus supplement, dated February&nbsp;12, 2018, in the form filed
with the Commission pursuant to Rule 424(b) of the Act relating to the offering of the Shares; and the final prospectus supplement, dated February&nbsp;13, 2018, in the form filed with the Commission pursuant to Rule 424(b) of the Act relating to
the offering of the Shares (together with the Base Prospectus, the &#147;Prospectus&#148;). In addition, we have examined originals or copies, certified or otherwise identified to our satisfaction, of such other instruments, documents, certificates
and records which we have deemed relevant and necessary for the basis of our opinion hereinafter expressed. In such examination, we have assumed: (i)&nbsp;the authenticity of original documents and the genuineness of all signatures; (ii)&nbsp;the
conformity to the originals of all documents submitted to us as copies; (iii)&nbsp;the truth, accuracy and completeness of the information, representations and warranties contained in the instruments, documents, certificates and records we have
reviewed; (iv)&nbsp;the Underwriting Agreement has been duly authorized and validly executed and delivered by the parties thereto (other than the Company); (v) that the shares of Common Stock will be issued and sold in compliance with applicable
U.S. federal and state securities laws and in the manner stated in the Registration Statement and the Prospectus; and (vi)&nbsp;the legal capacity of all natural persons. As to any facts material to the opinions expressed herein that were not
independently established or verified, we have relied upon oral or written statements and representations of officers and other representatives of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><SMALL>AUSTIN&nbsp;&nbsp;&nbsp;&nbsp;BEIJING&nbsp;&nbsp;&nbsp;&nbsp;BOSTON&nbsp;&nbsp;&nbsp;&nbsp;BRUSSELS&nbsp;&nbsp;&nbsp;&nbsp;HONG</SMALL>
<SMALL>KONG&nbsp;&nbsp;&nbsp;&nbsp;LOS</SMALL> <SMALL>ANGELES&nbsp;&nbsp;&nbsp;&nbsp;NEW</SMALL> <SMALL>YORK&nbsp;&nbsp;&nbsp;&nbsp;PALO</SMALL> <SMALL>ALTO</SMALL> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><SMALL>SAN</SMALL> <SMALL>DIEGO&nbsp;&nbsp;&nbsp;&nbsp;SAN</SMALL>
<SMALL>FRANCISCO&nbsp;&nbsp;&nbsp;&nbsp;SEATTLE&nbsp;&nbsp;&nbsp;&nbsp;SHANGHAI&nbsp;&nbsp;&nbsp;&nbsp;WASHINGTON</SMALL>, <SMALL>DC&nbsp;&nbsp;&nbsp;&nbsp;WILMINGTON</SMALL>, <SMALL>DE</SMALL> </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g522689g0216194247993.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pacific Biosciences of California, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">February&nbsp;20, 2018 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page 2 of 2 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We express no opinion herein as to the laws of any state or jurisdiction other than the General Corporation Law of the State of Delaware
(including the statutory provisions and all applicable judicial decisions interpreting those laws) and the federal laws of the United States of America. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We express no opinion as to (i)&nbsp;the effect of any bankruptcy, insolvency, reorganization, arrangement, fraudulent conveyance, moratorium
or other similar laws relating to or affecting the rights of creditors generally, (ii)&nbsp;rights to indemnification and contribution which may be limited by applicable law or equitable principles, or (iii)&nbsp;the effect of general principles of
equity, including, without limitation, concepts of materiality, reasonableness, good faith and fair dealing, the effect of judicial discretion and the possible unavailability of specific performance, injunctive relief or other equitable relief, and
the limitations on rights of acceleration, whether considered in a proceeding in equity or at law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On the basis of the foregoing, we are
of the opinion that the Shares, when issued, delivered and paid for in accordance with the terms of the Underwriting Agreement, will be validly issued, fully paid and <FONT STYLE="white-space:nowrap">non-assessable.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We hereby consent to the filing of this opinion as an exhibit to the Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> dated
as of the date hereof filed by the Company and incorporated by reference into the Registration Statement and to the use of our name wherever it appears in the Registration Statement, the Prospectus and in any amendment or supplement thereto. In
giving such consent, we do not believe that we are &#147;experts&#148; within the meaning of such term as used in the Act or the rules and regulations of the Securities and Exchange Commission issued thereunder with respect to any part of the
Registration Statement, including this opinion as an exhibit or otherwise. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">/s/ Wilson Sonsini Goodrich&nbsp;&amp; Rosati</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">WILSON SONSINI GOODRICH&nbsp;&amp; ROSATI</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Professional Corporation</TD></TR>
</TABLE></DIV>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g522689g0216194247993.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g522689g0216194247993.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  < -<# 2(  A$! Q$!_\0
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M!(P3M8'Z?0UFZM;0WWC#3+>YC$D)M)]T9)VM\T9Y'<94<'BL"X46OB.ZU.,
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-10 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g522689g37f45.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g522689g37f45.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ (@%@ P$1  (1 0,1 ?_$ (0    ' 0$! 0
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M'%"<JRF)0C!WI82\!S@+WSE_:*MZFBVRZYFE+[CUE>^_%-UO=VLLZ9DH=O\
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MIQDV#UG=$%0:K[F6/-XXT2>A+%L]:!W)@$'5U@@C"0B=HS#GAG+,2H4P4JL
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M(BG/21.,1Z,)51H#U*:/,K:RIU!Y9020''DMJ9,6<: D& 8$+&<X#C&/Z,<
MW)C4%36(<4HL"KZ[G1Y!A1Q!\QA,:DYQ)Q(,%DFE&/;8N&684#'*$6,XR''L
MQP#S*9V@EI"PDM;<4Q@0>Z@,Q2%,6T@:^X\+[M"W!*PC"@\-^S[G .[[OZ/9
MV>S@$%HKZ!1^/*XBPPB(,D4<,JLKXPT1IF;8\MRM+ 4MRK942(EM4Y5E%A";
MSE"[P(<8%VXQC@"!E45<<@3-1U;0$UK1J52Q(VF0Z.C0)5:X!):U4F1B;LIR
M%*PM.6$T80X$8$L.!9S@..P%9-"(6BD9TQ1Q"+I)<I0%-2B4IF!I(D9[63@
M26TY\*2 <S4!02PX"2(W)8<!QV8]F. 2 5/5A6781=:P L3\,\Q\R"&QT&7H
MQ2M Y*3';(6[&7$:AQ+"H'D[GR,\.!Y[18QG@/0565B/#7@=<P06&0.0LN!1
M"/BPT!RLRXY"UXRWY]WARX"R?V%<G[;//_6]O 'V2!0:,N2]XC<+B<?=W4Q4
M:Z.K)'&=I<G(U<J\<N,7KD"-.J6&+%O[8W)@A9,-^F+M%[> =G 14"B*/+D9
MLQ+IJJ2Y<>I\8?*05Y$0R,Y9S"'XLU\"SX<S%/./.>\R;D7;G.>WV\ \I-#H
MC-6P++,HM'):S@4$JP-,F8VQ^; JT^!83J@H'5*K2A4$8&+ !X!S!QG/9G';
MP!]6QLB]G-CJYG:UL?/0^ZSV)6WI%#.<V=UA/[N-;#B1HC$/<8P#N<@R7R8[
M.SL]G >$>C4<B+2G88I'V2,,:/)F4C-'FI RM*7)Q@C3LIVYM(3(R,FFCR(7
M*#',+.<Y]N> 9RZE:<=%$95N=35HXJH4_K97#5*Z"196?$I2Y)\(W&2QDT]J
M,,8G]>DQW1RQ+DI2:7]$0\X]G *#)5E8QE6O<(W7$#CZ]T+5E.:UDB$?:5;B
M4OSS+RUZE W)SEA:T7M.P8(6#,_UNW@#+/7%>QYI<6%@@<,8V)X3>#=V5GB[
M&VM+HCP28GPE<6Y$A)1KDWAS1E\AH!!Y!9#V=F<XX!&2TK3B!C:XPAJ6LT<:
M8U"U8RQY+ XLG8V=6Y P!Q5-;22U 0-ZAP!CL/&46 1N/8+.> <9$&A*:09E
MB:'19/*A$$)128B/-)4@$E3),-Z9-EY+2!<<D)T&,$ !WG* G')C& ^S@%9Y
M96:1M2]BD+2V/S(ZIC43HS/*!*Z-3DC.QRG)%[<N*/2+$QH?8(LP @"Q_3C@
M&T56-;$15!!2*]@Y,(:CTJEKAQ4382XJVJ42GQJ-0@CP$&&A&>D68[TH99(1
M%F_2#G O;P#W$' L9"+&!!%C(1!%C&<"QG'9G&<9]F<9QP#(BU8UM!EBMQA5
M>P>'N"],!&N71:)L,?6+4@#QJ@)5:EI0)#E*8"DP1F #$(.#!9%V=N<YX!%<
MZ/IIYGI]INU55ZXV4KC*F%KYZKB#"?+G.'K =VHBKL_C0Y<W:."!G.,(E)AJ
M8'-GE!CFSV@Z&Z"PAGC9L,:8;%6N'GE*23HHW1YH11LXE:(0EA1K$F1E-9A2
ML0LY-#DK.#,YSS=O )BJJJO70\FO5M;P)9 4YI!Y$'50^/*(>2>E5X7ICB8T
M:W#92S4Z[&#@"P1C(#?IX[!>W@#Y< @9)4D))A,1*)F1)2:7E%QMF 5*DY#>
M!I)(DA846 OA)+46%,$"K!H0IPX+QCDQV< GJ:IJY8WL32KK: JFJ+$'I8RV
M*8='3V^.)57)XI,Q(C6X29H(4]V'O )PEA'RX[<9[,< _N SQT>Z9VN.@TBV
MWD=+-)F%&X%[OUVS=*YHFW"2/)7=)D*&LH\6E3EX^X<<=7)W5H4Y_.(L3N<7
MG.0!!C 'NG=TX-?NFA6%DU7KZB6%LMGW;8=TOJYT(0@<BU,R=,CC\1).1$DX
M,CE>1=.D9VP(^TS*=-DT><FFF9R$.]7GI?,74[H&*19EG9U.;%T1.T%Q:PW8
MF3G*ON!9K-W)I!#TF38RK4Q1_,1)\+,$8R>G/2IE183!IL%& F4INSN-!H,T
MP+?#I]7Z"YF%M(9Y)8^J3/$MB*"M8]&GR0=,HMECE#7/845(LE=^8S/C&F&B
M,-R5@TP& BR%*>F#JU>C;U8^I]NW8&G\@H/7_:J.4VWT<NLPNJV:>^*KEG:V
M65%NE;Q61R)^B@)JM!EQR)1@K)G@P94_MQ!P$.D7"=/@P!V""<'%@$6 W!0,
M& +%V9$  ^7F" 60X[<8SV9[. *N+0U.Y913LV-[F40:$\DMQ1)EI9)P>S(3
MB@*2S0EFASCV"QV9QP"AP%3MZ+4L*CM1+^N*JEK&@GU95X[S2/'R5HR^L0CF
M')*Y40Z-8'!K-4I5" LT&>0\LP.18$'MSC <A36U=QMCX%K5N19[0TM+JEHN
M954TT5<SI6<D:FJZ6"9+*\23C(*Q6NS>ZKE\#>Y0O:"7! H*;W9207D@OG*4
M $"Q&]]YDVZN;'7T^IXQ*FFK]DR]?JOECLSN]8F.8G.?5S3RI_O2 N*M8_U<
M&L[:F+FF> 'X1'+F!G+<B4Z8M:2(03M_NI?=2;4TM25E/L0M6O-C8G:)L8E<
M;ABB#2ZL["J9D:92X(WYJ#))(V2"N9;'5QX4RS'AUC4ZD$)CQJ@KBAE!'6D6
MPEZ7Z0W.\\D(Q$)9=LQ&'Q*EH"11>&N*.H;OE=21-;'K04RA<RJ']4E8DZU6
MC 4>!4(2O!7<!3=F0*:([.W'L6Q5K*[$=U:4<A8[R72-I0T))(M7JL5?VT?7
ML?,C=K.<A7-HW4M$BPI,08PK$O*-/.!DD"7.! ;U\VHN2=S2Q:_M!O! ;]B]
M<V-+$FM$TKUSA+<]?=V7%,L1G=37U[Y>85;%0N)2E*C<7!)DQ6@5."8U42AR
M8%+D$2B=KK8LV!WV1*)%BO=A*NH]JFTDH.SZ0>:[E]33E0US!4-X)/42AUCU
MNT?(7:/B1-+VRKU1)F6]3@:W)PNZ)!P0W:6TY;$NGU 5+W#F"W]RJ,=+CD-A
M'1D_,78PQ*MH'/93&('#%#X'WI)W%589 &\A4XFX3,S:O6&A4#)P 0(CGLKL
MNR03?ZN5A];GWQJ/&XY+*RM8$3><UE9+'8,&<)M! 3> II(:[,$C:E["M:I"
MD0.@\"2B3.*3NL*@)BP,P3<JQ)_<5"41+T+70&P+?/)"P[)41(&L$G^]<10U
M!/IFR6=0$Y.7LX994+_*(<42F?4Z50<DP>:WNB1 Y%]W@'DEWA3F]0%/J88D
M8/N"^0*3L\:EQ0W43^KV)K]&RSV90)2$2<#(!C%4TF+5H30&C/,<F1V($''A
MO8$PT[:5AS'8_;RO)*MCQL%IM^IQHKU*VL:E ^E%S:J6B<R0Z2/!SJK3/ O>
MKKW:7N4R3!) .P?>"SS< M[@[ ?_ )6U?O/8G$:.F)M0UV_S)+&25 D8'A<W
MI\!0)5RX!1XVYHPM.+&M4X+,RF1A--P$60<N0*-ZR\*UCSW9%JV)#;'C;!5$
MCE<CB$$K=7'W',O8D2=_Y:_>#I>[G.$94MJ=:E*2N!!RTTW*4WQ(>TTO(5(S
MM-L(SU+J/ME[UK"?T]LA*]>629U5'(ZO2/L+C.T+O&H]!I+6L^!(E@YH[P![
MF3;EZ2+6T!;LWA6GIO C)+*$#&E>[E[1S>-WUY1&QA>PJ=K:>I.$L#S7;XQ,
MD@KN4Z[1F\[@<QW28^?==-:M>-3NK7M#(, 5#\E2A2D(S#3!J2 D+<'9Z^*>
MO\<"JYWCZU,+4*S;JA-:G53)9_)K0N:#6'"XU%ZY2+HJ[IG1O9YVFE>4(S"R
M F(5.2E/>Y* :5D)?6WG:MBWR@UIBRR/T;.&O62$[$SA;)68BQ'DM=/Y5(H4
MCA,3:0O$?:'1NA#W$UGO]T[P[',J;R20%>)R<$*Z/&Z%_P"-<@R5>V1F+V]7
MN]\9TZM5QB,%D5B1J8-&;@8Z]>Y]4T.+=\20*Q]B\F2N*1O/-<C6UU+/0F85
MX)R8,+3Z5;%/U\ZS);XL%PBH6!7(K3-C,V:$2R+))/4\,F4A9HM/)7#G=<XN
M5:2MPC[+WKXPK#Q*6A>6<4<!.8$28D(EU,V]F^Y$8V'CL>7Q.KK/K6SVH,47
M'1M[E*+_ &)L5&V3BH9BZQMX6152KE+S#!N#0YD!/+2HI"UJPAR,!/(('/IY
M8FQMRBM)^L.R8&K8ZSV"V5H4;''ZJ4,"QY+JB?*X9#9>!W43MZ"B6&IFTQ0X
M),IS23S#<!*$2$'TPB&N]U;5,U2I&QYN?#%MI;![<R75N-/H(ZL8(!"U +PM
M&KXY(WUFQ(5B]R,&QUID1:;#@G]Y2!P3HP#(+-#D(3G$+9O.,;0RW5VS'J*S
M)MD6OCK?537!&XD9'7:.BCDN:(!+H58L.R^.C0YGIW24MKFQKTAZ("Y,%:E/
M)"8E"H."K%>[T7L^5W4U:W8*O*-VKL)RI24UQ)FYB<7^C-J*?FLPA)$K=J6S
M('5 Z,5B,4*E@C'N)N*DQZ8EA059('%J,PHX#93@!P X < . ' #@!P X <
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BJOGWYT3^0GYI?Z8_#'?\!NIP X < . ' #@!P X <!__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
